AI Article Synopsis
- The study investigates the safety of etoricoxib, a cyclooxygenase-2 inhibitor, for patients who have adverse reactions to traditional NSAIDs.
- A trial with 37 NSAID-sensitive patients revealed that 34 tolerated etoricoxib without issues, while 3 (8%) experienced a generalized urticarial rash.
- The findings suggest that etoricoxib is generally well-tolerated in these patients, but recommend conducting a preliminary challenge test in a controlled setting before prescribing the medication.
Article Abstract
Background: The use of cyclooxygenase-2 inhibitors, a new class of analgesic drugs, is suggested in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs).
Objective: To evaluate tolerance to etoricoxib, a new cyclooxygenase-2 inhibitor, in NSAID-sensitive patients with urticaria-type adverse reactions.
Patients: Thirty-seven patients with adverse reactions to NSAIDs.
Methods: Single-blind, placebo-controlled oral challenge with increasing doses of etoricoxib.
Results: Thirty-four patients tolerated etoricoxib treatment without adverse reactions, but a generalized urticarial rash developed in 3 patients (8%).
Conclusions: Etoricoxib, like other cyclooxygenase-2 inhibitors, is a well-tolerated drug in most NSAID-sensitive patients. However, according to our experience, a previous challenge test in a safe environment may be necessary before prescribing the drug to such patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1081-1206(10)60691-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating potential unexpected adverse events and mortality after oral analgesics administration in fracture care-a cohort study.
Expert Opin Drug Saf
August 2024
Departments of Surgery, The Aga Khan University, Karachi, Pakistan.
Introduction: Analgesic selection per individual's tolerance is essential to avoid risks. The study evaluated current oral analgesic prescription practice, analgesic adverse effects-related factors, unexpected events, and mortality post-fracture surgery.
Research Design And Methods: The present prospective cohort study from June 2022 to July 2023 enrolled a total of 198 proximal femoral, ankle, and hindfoot trauma fracture patients.
Nimesulide-Induced Fixed Drug Eruption Followed by Etoricoxib-Induced Fixed Drug Eruption: An Unusual Case Report and Review of the Literature.
J Clin Med
March 2024
2nd Department of Dermatology and Venereology, Medical School, "Attikon" University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.
Article Synopsis
- A documented case highlights a patient who initially tolerated etoricoxib after a FDE from nimesulide but later developed an etoricoxib-induced FDE with severe symptoms.
- This suggests the need for more awareness in medicine regarding drug sensitivities and highlights the importance of further research to understand FDE mechanisms and improve diagnostics.
Nationwide Etoricoxib Injection Clinical Experience (NICE): Real-World Evidence in Indian Patients.
Cureus
February 2024
Medical Affairs, Zydus Lifesciences Ltd, Mumbai, IND.
Introduction Pain is a major health issue globally. Etoricoxib, a highly selective COX-2 inhibitor, given orally, has been found to be efficacious and safe in the management of acute and chronic pain. Oral etoricoxib has been extensively studied; however, there is a lack of research exploring the use of etoricoxib via alternative routes, specifically intramuscular (IM) injection.
View Article and Find Full Text PDFCase report: Sustained complete remission with all-oral MEPED therapy in a patient with Hodgkin's disease developing resistance to pembrolizumab.
Front Pharmacol
February 2024
Department of Internal Medicine III, Hematology and Oncology, University Hospital of Regensburg, Regensburg, Germany.
Targeted chemotherapy and immune checkpoint inhibitors (ICPi) have expanded the spectrum of therapies for patients with relapsed/refractory (r/r) Hodgkin's disease and significantly improved the proportion of patients with long-term disease control. However, there is no standardized therapeutic option in case of further progression. Recently, we demonstrated that therapy with MEPED (metronomic chemotherapy, everolimus, pioglitazone, etoricoxib, dexamethasone) is highly effective in patients with r/r Hodgkin's disease.
View Article and Find Full Text PDFEtoricoxib Coated Tablets: Bioequivalence Assessment between Two Formulations Administered under Fasting Conditions.
Pharmaceutics
November 2023
Clinical Research Unit, Medical Department, Adium S.A., São Paulo 04794-000, SP, Brazil.
Etoricoxib is a non-steroidal anti-inflammatory drug with high selectivity for cyclooxygenase 2 (COX-2), exerting a pronounced anti-inflammatory effect with fewer adverse events when compared to COX-1 inhibitors. The present study aimed to evaluate the bioequivalence between two etoricoxib-coated tablet formulations to meet regulatory requirements for a branded generic product registration in Brazil. A crossover study with an open-label, randomized design and a single-dose regimen with two treatments and two periods was conducted on healthy Brazilians of both genders.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!